Over the past 18 months, the Oral Thin Films industry trends have been shaped by strategic collaborations and technological advancements. Partnerships such as the alliance between Xpharma and BioFilmTech to co-develop pediatric drug delivery solutions underscore growing demand for patient-centric formulations. In mergers & acquisitions, the acquisition of OraFilm Innovations by OralCare Inc. in Q2 2024 strengthened market consolidation, expanding product portfolios in emerging markets. Regulatory shifts, including the FDA’s 2023 updated guidelines for fast-dissolving films, have driven quality control innovations. Product/technology launches highlight advancements in bioavailability, with companies like ThinPharma launching a line of films using nanocrystal technology for chronic disease management. Consumer trends increasingly favor discreet, portable dosing, particularly in mental health and geriatric care segments. Funding rounds have accelerated, with startups like BioOral securing $25M in Series B financing to scale production and enter Asia-Pacific markets. As the industry evolves, sustainability initiatives and digital health integrations are emerging as key differentiators, positioning Oral Thin Films as a cornerstone of modern drug delivery.
